Navigating Global Pharma Policy
Navigate the intricate dynamics of tariffs on the global pharmaceutical industry through this insightful content series. With contributions from A&M experts on both sides of the Atlantic, this series explores the economic, operational, and legal challenges posed by international trade policies. From the potential disruption of global supply chains to the strategic responses of leading pharmaceutical companies, A&M's Global Life Sciences team offers a comprehensive analysis of how the industry is navigating this evolving landscape.
Gain valuable perspectives on financial optimization, supply chain resilience, and regulatory compliance, as well as the broader geopolitical implications of these tariffs. Whether you're a stakeholder in the pharmaceutical sector or simply interested in the intersection of trade and healthcare, this series provides actionable insights and thought leadership from professionals deeply embedded in the industry.
How US Policy Could Reshape Global Pharma Research and Development
The Profit Crunch
US pharmaceutical companies have long been leaders in global foreign direct investment, accounting for 25% of outbound FDI in the sector and over half of global pharmaceutical R&D spending. This dominance has been fuelled by the strong profitability of the US market, where higher drug prices have historically funded substantial investments in R&D and manufacturing abroad. These investments have enabled US firms to access global talent, diverse patient populations, and benefit from favourable tax policies and pricing structures in other regions.
This leadership, however, is now facing uncertainty due to tariffs, pricing reforms, and changes to reimbursement policies, which threaten US market profitability and could disrupt global R&D strategies and FDI flows. As policy pressures mount, emerging life science hubs in developing economies and advancements in technology and digital capabilities are expected to play a growing role in reshaping global pharmaceutical innovation.
Stay informed as we continue to explore the evolving landscape of U.S. trade policies and their impact on the global pharmaceutical industry. This series will be updated regularly to reflect the latest developments, offering fresh insights and strategies to navigate the challenges ahead. Follow along as we analyze policy shifts, industry responses, and the broader implications for global healthcare and trade.
EXPLORE OTHER PARTS OF THIS SERIES
The Effect of Trump's Tariffs on the European Pharma Industry | |||
| 
| 
| 
|
The Profit Crunch: How US Policy Could Reshape Global Pharma R&D | |||
|
